The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Oral roflumilast for plaque psoriasis: Results from a 24-week real-world study
|
Psoriasis is associated with significant physical and psychological burden for patients, with frequent comorbidities such as obesity and cardiovascular disease. Current treatment options such as biologics, small molecules, and conventional systemic therapies are limited by safety and accessibility issues and the need for laboratory monitoring in some patients. The PDE-4 inhibitor roflumilast has shown efficacy in treating moderate to severe plaque psoriasis; however, real-world outcomes data are limited.1 A prospective cohort study was conducted at a single center in Portugal, evaluating the real-world effectiveness and safety of oral roflumilast (500 µg once daily) in 58 adults with moderate-to-severe plaque psoriasis. Results were published in the Journal of Dermatological Treatment by Lé et al.1 |
| Key learnings |
| Significant improvements in PASI score were observed at Week 24, with 63.0% of patients achieving PASI <5, 47.8% achieving PASI <3, and 21.7% reaching PASI <1. |
| Notably, 53.4% of patients experienced weight loss, with a mean reduction of 6 kg bodyweight (±4.3 kg), highlighting a potential benefit in patients with comorbid obesity. |
| Mild GI symptoms (diarrhea, nausea, dyspepsia) were common (44.8% of patients) but rarely led to discontinuation. No SAEs were reported. 24.1% of patients discontinued treatment due to lack of response. |
| The oral administration, lack of need for laboratory monitoring, and weight loss benefit make roflumilast a viable alternative to biologics and other systemic therapies, particularly for patients with comorbidities or limited access to biologics. |
Abbreviations: GI, gastrointestinal; PASI, Psoriasis Area and Severity Index; PDE-4, phosphodiesterase 4; SAE, serious adverse event.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
